A study involving 77 women with early stage breast cancer who underwent Oncotype DX, a genomic test that provides recurrence risk estimates to help plan adjuvant treatment, found that about one-third of patients did not fully understand subsequent discussions about their test results.
A study involving 77 women with early stage breast cancer who underwent Oncotype DX, a genomic test that provides recurrence risk estimates to help plan adjuvant treatment, found that about one-third of patients did not fully understand subsequent discussions about their test results. Investigators used mailed surveys, supplemented by medical chart review, to assess how the patients received and understood their recurrence risk information on the basis of the test. The study appeared in the journal Cancer.
Study participants had estrogen receptor-positive disease with 0 to 3 positive lymph nodes. Cancer recurrence risk was low in 50% of participants and intermediate in 37%. Most women (71%) accurately recalled their recurrence risk on the basis of the test, with a smaller proportion (67%) thinking that they understood much of what they were told about it. About 25% of participants recalled feeling anxious on hearing the results.
Women's perceived recurrence risk was associated not only with their actual genomic-based recurrence risks but also with having had a previous cancer diagnosis and being worried about recurrence.
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
Preference for alternative contraceptive sources reported by many patients
October 31st 2024With nearly half of short-acting contraceptive users preferring non-traditional sources such as telehealth and over-the-counter options, a recent study highlights evolving patient needs in contraceptive access.
Read More